Work

Management of Brain Metastases from Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Cancer

Year: 2022

Type: review

Abstract: In the past 5 years, the treatment options available to patients with HER2+ breast cancer brain metastasis (BCBM) have expanded. The longer survival of patients with HER2+ BCBM renders understanding the toxicities of local therapies even more important to consider. After reviewing the available literature for HER2 targeted systemic therapies as well as local therapies, we present a simplified algorithm for when to prioritize systemic therapies over local therapies in patients with HER2+ BCBM.

Source: Cancers

DOI: 10.3390/cancers14205136

Authors: Tresa M. McGranahan, Alipi V. Bonm, Jennifer M. Specht, Vyshak Venur, Simon S. Lo

Institutions: University of Washington, Fred Hutch Cancer Center

Language: English

Topic: Brain Metastases and Treatment

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,513